text_1: Erbitux OK for colorectal cancer patients with genetic marker
text_2: "This report describes a study showing that colon cancer patients whose tumors have a certain genetic mutation don’t benefit from the drug Erbitux. Since that drug is expensive and has serious side effects, it’s important to know which patients will benefit. This study confirms previous research into the question. The story follows nearly all medical journalism best practices, as the ratings show. It could have been improved in two ways:  It might have put the studied treatment in context to other clinical approaches used to treat metastatic colon cancer. In the second paragraph, it says that the drug ""doesn’t work"" in patients whose tumors have the genetic mutation. But it does not return to verify or elaborate on this point in less vernacular language. For instance, later on the story reports that patients whose tumors do not have the mutation showed significant tumor shrinkage. It would have been useful to reiterate that patients who did have the mutation and took Erbitux saw outcomes no different from those taking the placebo–the core finding that supports the ""doesn’t work"" formulation at the top of the story. It’s also important to note that tumor shrinkage should not be equated with considerable benefit – which should be expressed in terms of improved survival, lower recurrence or improved quality of life. Overall, though, this story was well done, and it took only 391 words to do such a good job."